TRAIL is a potent inducer of apoptosis in most cancer cells, but not in normal cells, and therefore has deserved intense interest as a promising agent for cancer therapy. In the search for bioactive natural products for overcoming TRAIL-resistance, we previously reported a number of active compounds. In our screening program on natural resources targeting overcoming TRAIL-resistance, activity-guided fractionation of the MeOH extract of Datura stramonium leaves led to the isolation of three alkaloids -scopolamine (1), trigonelline (2), and tyramine (3). Compounds 1, 2, and 3 exhibited TRAIL-resistance overcoming activity at 50, 150, and 100 µM, respectively in TRAIL-resistant AGS cells.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily, which initiates apoptosis in cancer cells through interaction with death receptors DR4 and DR5. TRAIL is perceived as an attractive chemotherapeutic agent as it specifically targets cancer cells while sparing normal cells [1] . The relative absence of side effects and antitumor properties of TRAIL make it a promising and potential cancer therapeutic agent. TRAIL is thought to be important in host tumor surveillance and metastasis suppression, and various therapeutic agonists that activate TRAIL receptors to induce tumor cell apoptosis are in clinical development [2] .
Apoptosis is essential for maintenance of tissue homeostasis and removal of unwanted cells. Apoptosis is triggered by either extrinsic or intrinsic stimuli. TRAIL activates the extrinsic apoptotic pathway upon binding to its cell surface death receptors -DR4 and DR5. Ligation of TRAIL to its receptor results in trimerization of the receptor and clustering of the receptor's intracellular death domain (DD), leading to the formation of the death-inducing signaling complex (DISC). Trimerization of the DDs leads to the recruitment of an adaptor molecule, FADD (Fas-associated death domain), and subsequent binding and proteolytic activation of caspase-8 and -10. Activated caspase-8 and -10 then cleave caspase-3 leading to apoptosis [3] . Proteolytic activated caspase-8 further activates Bid, which in turn, translocates to the mitochondria and activates mitochondrial pathways. The translocation of truncated Bid to the mitochondria promotes cytochrome c release through interaction with mitochondrial membrane proteins Bax and Bak. Cytochrome c then binds to the adaptor apoptotic protease activating factor 1 (Apaf-1) and pro-caspase-9 to form an apoptosome, leading to the activation of caspase-9. Activated caspase-9 serves as initiator caspase to activate executioner caspase-3, -6, and -7, which cause cell death.
However, the major limitation of the TRAIL therapy is the development of TRAIL resistance through a variety of mechanisms in cancer cells such as gastric cancer, breast cancer, lung cancer, prostate cancer and colon cancer. Resistance to TRAIL can occur at different points in the signaling pathways of TRAIL-induced apoptosis. Dysfunction of the death receptors DR4 and DR5 due to mutation, over expression of Bcl-2 or Bcl-X (L), and loss of Bax or Bak function, have been reported to result in TRAIL-resistance [4] .
Overcoming TRAIL-resistance and understanding the mechanism of such resistance are thus very important in anticancer drug discovery. Different chemotherapeutic agents, including a number of natural products, are reported to have TRAIL-resistance overcoming activity. For example, parviflorene F [5] , fuligocandin B [6], 1-O-formylrocagloic acid [7] , artonin E [8] , xanthinosin, and lasidio p-methoxybenzoate [9] were reported to overcome TRAILresistance. Therefore, to enhance the TRAIL mediated apoptosis, the combination of TRAIL along with TRAIL sensitizing agents possibly represents the best clinical option to overcome TRAILresistance.
The TRAIL-resistance overcoming activity of the extract was assessed by comparing cell viability in the presence and absence of TRAIL against TRAIL-resistant human gastric adenocarcinoma AGS cell lines. Twenty-five % difference in viability between the presence and absence of TRAIL means that the compound is overcoming TRAIL-resistance, and a greater difference in viability indicates strong TRAIL-resistance overcoming activity. After initial screening of the plant extracts library, the MeOH extract of Datura stramonium L. (Solanaceae) leaves was found to be active in overcoming TRAIL-resistance. D. stramonium is a wild growing, flowering annual plant that has been investigated as a source of the tropane alkaloids atropine and scopolamine. The plant is also known as Jimson weed and is collected from Natore, Bangladesh. Fruits are large and thorny (hence the English name "thorn apple") [10] .
Datura is used internally in relieving the spasm of bronchitis and asthma. It is also used in the treatment of Parkinsonism and hemorrhoids. Its leaves, applied after roasting, are useful in relieving pain [11] . The tropane alkaloids, hyoscyamine and scopolamine, and several minor alkaloids have been identified in Datura species. Typical examples of minor alkaloids are tigloidin, aposcopolamine, apoatropin, hyoscyamine N-oxide, and scopolamine N-oxide [10] . Bioassay-guided fractionation of the MeOH extract of D. stramonium leaves led to the isolation of three alkaloids (1) (2) (3) . Here, we report the isolation, structure elucidation, and the TRAIL-resistance overcoming activity of the isolated compounds in TRAIL-resistant human gastric adenocarcinoma (AGS) cells.
The MeOH extract of D. stramonium leaves, which exhibited TRAIL-resistance overcoming activity (41% more inhibition than the agent alone) at 10 µg/mL, was subjected to Diaion HP20 column chromatography. Activity-guided fractionation using silica gel, LH-20, octadecylsilyl (ODS), and preparative HPLC yielded scopolamine (1) [12], trigonelline (2) [13] , and tyramine (3) [14] by comparison of their spectroscopic data with that in the literature.
The activities of the isolated compounds were evaluated using TRAIL resistant human gastric adenocarcinoma (AGS) cell lines. All compounds showed activity, as shown in Figure 1 . Treating cells with 10, 20, and 50 µM of 1 along with TRAIL (100 ng/mL) resulted in 23%, 26%, and 42% more inhibition than the agent alone, showing its good TRAIL-resistance overcoming activity. Combined treatment of TRAIL (100 ng/mL) and 2 (50, 100, and 150 µM) resulted in 15%, 19%, and 44% more inhibition than the agent alone, indicated its good TRAIL-resistance overcoming activity. Compound 3 at 10, 50, and 100 µM along with TRAIL (100 ng/mL) resulted in 19%, 23%, and 32% decrease in cell viability than treatment with compound alone (without TRAIL) showing moderate TRAIL-resistance overcoming activity.
A previous study reported that 1 has acetylcholine esterase and protease inhibitory activity and thereby improving Alzheimer's disease and dementia [15] . Compound 1 also reduced persistent activity related to long-term encoding in the parahippocampal gyrus during delayed matching in humans [16] . Compound 2 showed antidiabetic activity [17] , anti-invasive activity against hepatoma cell line (AH109A) [18] , and also induced neurite outgrowth in human neuroblastoma SK-N-SH cells [19] . Compound 3 showed vasorelaxant [20] and non-specific stimulant activity on an isolated intestinal preparation [21] .
Owing to the selectivity of TRAIL towards cancer cells, this ligand remains promising as a potential cancer therapeutic agent. Efforts to identify agents that target death receptors directly or which confer synergy with TRAIL may be useful for cancer therapy. Understanding the mechanism of TRAIL-resistance and developing strategies are important for successful use of TRAIL in cancer therapy. Combined treatment with chemotherapeutic agents, including natural products, can overcome such resistance and enhance the therapeutic potential of TRAIL. In this paper, we reported for the first time the TRAIL-resistance overcoming activity of scopolamine, trigonelline, and tyramine in TRAIL resistant AGS cells, thereby suggesting their possible use in combination with TRAIL against AGS cells.
Experimental

Plant material and preparation of extract:
The leaves of D. stramonium L. were collected from Natore, Bangladesh. A voucher specimen KKB186 is preserved in the Laboratory of Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan. The air-dried and ground D. stramonium leaves (66 g) were subjected to extraction with MeOH for 2 days at room temperature, followed by homogenization, filtration, evaporation and vacuum desiccation overnight to obtain the crude extract (5 g, 7.58%, w/w).
Isolation of compounds from D. stramonium extract:
The MeOH extract was chromatographed on Diaion HP-20 (φ 5 x 25 cm), particle size 250-850 µm, using MeOH/acetone to remove the chlorophyll and afforded 4 fractions 1A to 1D. The active fraction 1B (1 gm) was subjected to silica gel PSQ 100 column chromatography (φ 2.2 x 29 cm) and eluted with CHCl 3 : MeOH (10:0-0:1, then washed with 1% TFA with MeOH) to afford the fractions 2A-2M. 2F (270 mg) was subjected to silica gel 60N column chromatography (φ 2.4 x 48 cm) and eluted with CHCl 3 : MeOH (10:0-0:1, then washed with 1% TFA with MeOH) to afford fractions 8A-8N and compound 1 (8 mg). Fraction 1B (1.4 g) was again fractionated by silica gel PSQ 100 column chromatography (φ 2.7 x 32 cm) using CHCl 3 : MeOH (10:0-0:1) as the eluting solvent then washed with 1% TFA with MeOH to afford fractions 10A-10R and compound 2 (7.4 mg). 10J (241.5 mg) was subjected to silica gel 60N column chromatography (φ 2.4 x 30 cm) and eluted with CHCl 3 : MeOH (10:0-0:1, then washed with 1% TFA with MeOH) to afford fractions 11A-11W. 11P (25 mg) was again fractionated by Sephadex LH-20 column chromatography (φ 1.2 x 33 cm) using MeOH as the solvent system to afford fractions 12A-12G and compound 3 (1.4 mg).
Cell cultures and viability assay (FMCA):
AGS cells were purchased from ATCC. AGS cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Wako, Osaka, Japan) with 10% FBS (fetal bovine serum) and 1% penicillin-streptomycin. Culture was maintained in a humidified incubator at 37°C in 5% CO 2 /95% air. Cell viability was assessed using a fluorometric microculture cytotoxicity assay (FMCA) in the presence and absence of TRAIL using TRAIL-resistant AGS cells. Cells were seeded in a 96-well culture plate (6 x 10 3 cells per well) in 200 µL of medium containing 10% FBS. They were then incubated at 37°C in a 5% CO 2 incubator for 24 h. Test samples at different doses with or without TRAIL (100 ng/mL) were added to each well. After 24 h incubation, the cells were washed with PBS, and 200 µL of PBS containing fluorescein diacetate (10 µg/mL) was added to each well Compounds from Datura stramonium with TRAIL-resistance overcoming activity Natural Product Communications Vol. 11 (2) 2016 187 [22] . The plates were incubated at 37°C for 1 h, and fluorescence at 538 nm with excitation at 485 nm was measured using Fluoroskan Ascent (Thermo Fisher Scientific, Waltham, MA, USA). Luteolin (purity ≥ 98%, Sigma-Aldrich) was used as a positive control.
